ALKS:NSD-Alkermes Plc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 29.65

Change

+0.15 (+0.51)%

Market Cap

USD 5.01B

Volume

0.42M

Analyst Target

USD 19.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

-0.09 (-0.72%)

USD 15.08B
NBIX Neurocrine Biosciences Inc

-0.46 (-0.34%)

USD 12.97B
ITCI Intracellular Th

+1.24 (+1.48%)

USD 8.85B
LNTH Lantheus Holdings Inc

+0.29 (+0.32%)

USD 6.19B
ALVO Alvotech

+0.04 (+0.32%)

USD 3.47B
HCM HUTCHMED DRC

+0.05 (+0.35%)

USD 2.94B
AMPH Amphastar P

-0.85 (-2.17%)

USD 2.09B
SUPN Supernus Pharmaceuticals Inc

+0.01 (+0.03%)

USD 2.05B
EVO Evotec SE ADR

+0.54 (+12.11%)

USD 1.70B
DVAX Dynavax Technologies Corporati..

+0.01 (+0.08%)

USD 1.69B

ETFs Containing ALKS

PSIL AdvisorShares Psychedelic.. 6.46 % 0.00 %

+0.21 (+0.46%)

USD 6.05M
IBRN iShares Trust - iShares N.. 4.57 % 0.00 %

+0.02 (+0.46%)

USD 3.86M
SBIO ALPS Medical Breakthrough.. 3.78 % 0.50 %

-0.04 (0.46%)

USD 0.11B
TYNE 3.26 % 0.00 %

N/A

N/A
RTWO:LSE L&G Russell 2000 US Small.. 0.65 % 0.00 %

+0.39 (+0.46%)

USD 0.23B
RTWP:LSE Legal & General UCITS ETF.. 0.65 % 0.00 %

-12.00 (0.46%)

USD 0.23B
ETLZ:XETRA L&G Russell 2000 US Small.. 0.65 % 0.00 %

N/A

USD 0.09B
GVLU Tidal ETF Trust 0.51 % 0.00 %

+0.11 (+0.46%)

USD 0.18B
LABS 0.00 % 0.45 %

N/A

N/A
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

+0.19 (+0.46%)

USD 0.19B
AFSM First Trust Active Factor.. 0.00 % 0.00 %

+0.23 (+0.46%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.89% 68% D+ 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.89% 68% D+ 58% F
Trailing 12 Months  
Capital Gain 6.39% 67% D+ 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.39% 67% D+ 57% F
Trailing 5 Years  
Capital Gain 42.89% 80% B- 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.89% 80% B- 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 12.10% 57% F 64% D
Dividend Return 12.10% 57% F 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.21% 86% B+ 66% D+
Risk Adjusted Return 44.46% 87% B+ 74% C
Market Capitalization 5.01B 94% A 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.